全文获取类型
收费全文 | 592篇 |
免费 | 61篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 27篇 |
妇产科学 | 10篇 |
基础医学 | 67篇 |
口腔科学 | 14篇 |
临床医学 | 26篇 |
内科学 | 135篇 |
皮肤病学 | 8篇 |
神经病学 | 20篇 |
特种医学 | 3篇 |
外科学 | 229篇 |
综合类 | 8篇 |
预防医学 | 34篇 |
眼科学 | 24篇 |
药学 | 29篇 |
中国医学 | 1篇 |
肿瘤学 | 19篇 |
出版年
2023年 | 2篇 |
2022年 | 7篇 |
2021年 | 16篇 |
2020年 | 17篇 |
2019年 | 32篇 |
2018年 | 29篇 |
2017年 | 24篇 |
2016年 | 17篇 |
2015年 | 16篇 |
2014年 | 20篇 |
2013年 | 44篇 |
2012年 | 48篇 |
2011年 | 54篇 |
2010年 | 30篇 |
2009年 | 21篇 |
2008年 | 34篇 |
2007年 | 37篇 |
2006年 | 38篇 |
2005年 | 31篇 |
2004年 | 21篇 |
2003年 | 16篇 |
2002年 | 13篇 |
2001年 | 7篇 |
2000年 | 6篇 |
1999年 | 6篇 |
1998年 | 3篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1993年 | 3篇 |
1992年 | 3篇 |
1988年 | 6篇 |
1986年 | 3篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1974年 | 2篇 |
1973年 | 4篇 |
1972年 | 5篇 |
1971年 | 5篇 |
1970年 | 3篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1967年 | 1篇 |
1966年 | 3篇 |
1965年 | 2篇 |
1964年 | 1篇 |
1962年 | 2篇 |
1960年 | 2篇 |
1947年 | 1篇 |
排序方式: 共有656条查询结果,搜索用时 562 毫秒
61.
Chronic allograft nephropathy is characterized by an increase over time of interstitial fibrosis, tubular atrophy, fibrointimal thickening, arteriolar hyalinosis and glomerulosclerosis, resulting in progressive renal dysfunction. It is mainly caused by calcineurin inhibitors-induced nephrotoxicity, which is related to an imbalance between vasoconstrictor and vasodilator factors. Cyclosporine A-induced nephrotoxicity is particularly due to the activation of pro-apoptotic genes leading to tubular atrophy with tubular cell apoptosis and to hemodynamic changes inducing interstitial fibrosis by the activation of factors stimulating the fibroblast proliferation (TGFbeta, Endothelin-A and Plasminogen activator inhibitor-1). Calcineurin inhibitors (CNI) treatment monitoring is essentially based on histology, but a better follow-up of drug exposure post-transplantation leading to a regular and rapid adjustment of the doses to avoid extended periods of overexposure, could enable to decrease their nephrotoxicity and improve graft survival in treated patients. CNIs dose reduction or conversion to proliferating signal inhibitors may be a therapeutic alternative. 相似文献
62.
63.
Guitard J Sandres-Sauné K Kamar N Ribes D Faguer S Esposito L Lavit M Muscari F Péron JM Lavayssière L Durand D Rostaing L 《Transplantation proceedings》2007,39(8):2603-2605
We assessed whether conversion from tacrolimus (TAC) to cyclosporine (CsA) was associated with a reduction in hepatitis C virus (HCV) viral load among HCV-positive liver transplant (OLT) patients. PATIENTS AND METHODS: Nine OLT patients with recurrent HCV have TAC and prednisone immunosuppression. None received any HCV antiviral therapy. After the last intake of TAC, the patients underwent a 12-hour area under the curve (AUC(12)) measurement of both TAC and HCV viral loads. The next morning (D(0)) patients were given CsA (4 mg/kg bid). At the first intake of CsA and at 1 month (M(1)) later, the patients underwent AUC(12) for CsA and HCV viral loads. Biological data, including aspartate (AST) and alanine (ALT) aminotransferase, gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (AP), and bilirubin levels, were collected during AUC(12), and at M(1) and M(3). RESULTS: With respect to liver enzymes (AST, ALT, GGT), there was no significant difference between D(0), M(1), and M(3). Conversely, there was a significant decrease in AP between D(0) and M(3) (P = .02), and a significant increase in total bilirubin between D(0) and M(1) (P = .04), and between D(0) and M(3) (P = .01). HCV viral load significantly increased by M(3) (P = .01). At no time (D(0), M(1)) was there any correlation between the AUC(12) of TAC or CsA, and between AUC(12) HCV viral load. CONCLUSION: This pilot study found no acute or chronic anti-HCV effects from CsA that were evident within 12 hours after CsA administrations or beyond 1 month of CsA therapy, respectively. 相似文献
64.
Böhler T Guillebaud J Etienne L Canivet C Kamar N Rostaing L Thiers JC Galvani S Augé N Salvayre R Nègre-Salvayre A Thomsen M 《Transplantation proceedings》2007,39(8):2624-2626
BACKGROUND: Hyperproliferation of smooth muscle cells (SMCs) plays a key role in allograft arteriosclerosis. This prompted us to investigate the effect of the novel immune modulator and synthetic sphingolipid FTY720 on apoptosis of SMCs. METHODS: Rabbit SMC cultures were treated with FTY720 and apoptosis and necrosis were detected by fluorescence microscopy. RESULTS: We investigated dose- and time-dependent effects of FTY720 and found that clinically relevant low doses of FTY720 (<1 micromol/L) did not induce apoptosis, whereas 10 micromol/L FTY720 induced apoptosis after 48 hours incubation. CONCLUSION: At doses of FTY720 used in clinics for treatment of renal allografts and multiple sclerosis. FTY720 did not induce SMC apoptosis. 相似文献
65.
BACKGROUND: The impact of posttransplant anemia (PTA) upon patient and graft survival remains controversial. The aim of this study was to assess the incidence of PTA 1 year after transplantation in patients treated with calcineurin inhibitors and mycophenolate mofetil, and to determine the impact of 1-year PTA upon long-term patient and graft survival. METHODS: Between January 1, 1999, and December 31, 2003, all patients with a functioning graft at 1 year, and who were receiving an immunosuppressive regimen based on calcineurin inhibitors and mycophenolate mofetil, were included in the study (n=339). Anemia was defined according to the World Health Organization criteria, that is, hemoglobin levels less than 13 g/dL for men and less than 12 g/dL for women. RESULTS: One hundred and eight of 339 were anemic at 1 year after transplantation (31.85%; group I). Independent predictors for 1-year anemia are donor's age and serum creatinine at 6 months. At last follow-up, that is, 69.4+/-17.7 months after transplantation, there had been a significant number of deaths in group I (n=7; 6.9%) compared with nonanemic patients (group II) (n=4; 1.73%; P=0.04). Mean allograft survival was significantly better in group II (70.7+/-17.1 months) compared with group I (66.4+/-18.7 months; P=0.03). Also, 12 graft losses (11.1%) were observed in group I and seven occurred in group II (3%; P=0.004). Independent predictors for allograft loss included delayed graft function and serum creatinine at 1 year. CONCLUSION: After kidney transplantation, the occurrence of PTA at 1 year is harmful, in the long term, to patient survival. 相似文献
66.
67.
68.
Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow Transplant 总被引:22,自引:4,他引:18
69.
Schistosoma mansoni and HIV acquisition in fishing communities of Lake Victoria,Uganda: a nested case–control study 下载免费PDF全文
Ali Ssetaala Jessica Nakiyingi‐Miiro Gershim Asiki Nassim Kyakuwa Juliet Mpendo Govert J. Van Dam Paul L. Corstjens Pietro Pala Leslie Nielsen Jan De Bont Giuseppe Pantaleo Noah Kiwanuka Pontiano Kaleebu Anatoli Kamali Alison M. Elliott 《Tropical medicine & international health : TM & IH》2015,20(9):1190-1195
70.
J. Izopet S. Lhomme S. Chapuy-Regaud J.-M. Mansuy N. Kamar F. Abravanel 《Transfusion Clinique et Biologique》2017,24(3):176-181
HEV infections are mainly food- and water-borne but transfusion-transmission has occurred in both developing and developed countries. The infection is usually asymptomatic but it can lead to fulminant hepatitis in patients with underlying liver disease and pregnant women living in developing countries. It also causes chronic hepatitis E, with progressive fibrosis and cirrhosis, in approximately 60% of immunocompromised patients infected with HEV genotype 3. The risk of a transfusion-transmitted HEV infection is linked to the frequency of viremia in blood donors, the donor virus load and the volume of plasma in the final transfused blood component. Several developed countries have adopted measures to improve blood safety based on the epidemiology of HEV. 相似文献